3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Taste Disorders
1
Neoplasms
1
Malnutrition
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Extranodal NK-T-Cell
1
Interventions
pegaspargase
5
tislelizumab
2
selinexor
2
fludarabine phosphate
2
Whole-Body Irradiation
2
Tacrolimus
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Oxaliplatin
2
Mycophenolic Acid
2
Gemcitabine
2
Etoposide
2
Cyclophosphamide
2
Busulfan
2
Azacitidine
2
Asparaginase
2
sugemalimab
1
relatlimab
1
pembrolizumab
1
gemcitabine-oxaliplatin regimen
1
fludarabine
1
Vorinostat
1
Valganciclovir
1
Transplantation
1
Tomography, X-Ray Computed
1
Thiotepa
1
Therapeutics
1
Sirolimus
1
Positron-Emission Tomography
1
Polymerase Chain Reaction
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Extranodal NK-T-Cell
×
Ice
×
1 year
×
Clear all
NCT04425070
2026-01-05
TOUCH
Antengene Corporation
Phase 1/2
Terminated
56 enrolled